Immuno-oncology treatment for multiple myeloma gets US approval

30 Nov 2015

The U.S. Food and Drug Administration approved Bristol-Myers Squibb’s drug for the treatment of a form of blood cancer.

The approved treatment is Empliciti and it will be used in multiple myeloma patients in combination with Celgene's Revlimid and common anti-inflammatory drug dexamethasone.

CareAcross-medication-container

 

Research has shown that combination treatments increase the time that multiple myeloma patients survive without the disease.

According to the FDA, Empliciti is the second immuno-oncology treatment for multiple myeloma to be approved, after Johnson & Johnson's Darzalex.

 

Source: Reuters

Login to your account

Did you forget your password?